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Abstract
Background: We have shown previously that murine gammaherpesvirus 68 (gHV68) infection exacerbates
established pulmonary fibrosis. Because Toll-like receptor (TLR)-9 may be important in controlling the immune
response to gHV68 infection, we examined how TLR-9 signaling effects exacerbation of fibrosis in response to viral
infection, using models of bleomycin- and fluorescein isothiocyanate-induced pulmonary fibrosis in wild-type (Balb/
c) and TLR-9
-/- mice.
Results: We found that in the absence of TLR-9 signaling, there was a significant increase in collagen deposition
following viral exacerbation of fibrosis. This was not associated with increased viral load in TLR-9
-/- mice or with
major alterations in T helper (Th)1 and Th2 cytokines. We examined alveolar epithelial-cell apoptosis in both strains,
but this could not explain the altered fibrotic outcomes. As expected, TLR-9
-/- mice had a defect in the production
of interferon (IFN)-b after viral infection. Balb/c fibroblasts infected with gHV68 in vitro produced more IFN-b than
did infected TLR-9
-/- fibroblasts. Accordingly, in vitro infection of Balb/c fibroblasts resulted in reduced proliferation
rates whereas infection of TLR-9
-/- fibroblasts did not. Finally, therapeutic administration of CpG
oligodeoxynucleotides ameliorated bleomycin-induced fibrosis in wild-type mice.
Conclusions: These results show a protective role for TLR-9 signaling in murine models of lung fibrosis, and
highlight differences in the biology of TLR-9 between mice and humans.
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive,
fibrotic lung disease with a poor survival rate. Causes of
IPF may relate to epithelial-cell injury, abnormal fibro-
proliferation, inflammation, and deposition of extracellu-
lar matrix components [1,2]. Standard therapies have
shown little benefit, and most patients progress to
respiratory failure.
Many patients with IPF have a slow progressive dis-
ease course over months to years after diagnosis [3];
however, some patients experience acute deterioration
in pulmonary function [3-7] without clear cause. This is
referred to as acute exacerbation of IPF. Histological
findings are diffuse alveolar damage or organizing pneu-
monia plus usual interstitial pneumonitis [4-7]. Reported
mortality rates are often greater than 78% in this popu-
lation of patients [7].
Viral infections have been linked to the development
of fibrosis in both human and animal studies [8-13]. We
have shown previously that gHV68 infection augments
fluorescein isothiocyanate (FITC)-induced pulmonary
fibrosis when given 14 days after fibrotic challenge [14].
This exacerbation of fibrosis caused by gHV68 shares
many similarities with acute exacerbations in humans,
including decreased lung compliance and diffuse alveo-
lar damage on histopathology [14].
The pathogenesis of IPF is unclear. Many cell types
have been implicated in the pathogenesis of the fibrotic
response, including mesenchymal cells [15-17] and
alveolar epithelial cells (AECs) [18]. AECs are closely
approximated to the mesenchymal (fibroblast) cells
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role in homeostasis between epithelial and mesenchymal
cells. AEC injury is a universal feature seen in the
pathobiology of fibrotic lung disease [19], and there is
good evidence that AEC apoptosis plays a role in the
pathogenesis of pulmonary fibrosis [20-22]). A role for
gammaherpesviral infection in the induction of AEC
apoptosis has been suggested. Egan et al.r e p o r t e dt h a t ,
compared with controls, patients with IPF had increased
Epstein-Barr virus (EBV) DNA loads in lung tissue, and
some of these patients also had positive staining for p53,
suggesting an increase in apoptosis [10]. Additionally, in
vitro infection of human lung epithelial cells with EBV
induced secretion of transforming growth factor (TGF)-
b1 secretion and upregulated caspases 3 and 7 [23].
However, mechanistic studies using animal models have
not been carried out.
The human immune system has a series of 10 innate
immune receptors known as Toll-like receptors (TLRs),
which enable host cells to recognize foreign pathogens.
TLR-9 is an endosomal receptor that recognizes
unmethylated CpG nucleotides, which are commonly
found in bacterial and viral DNA genomes [24]. Stimu-
lation of TLR-9 results in activation of the MyD88 path-
way, resulting ultimately int h ea c t i v a t i o no fJ u nN -
terminal kinase and the translocation of nuclear factor
(NF)B to the nucleus [24]. TLR-9 stimulation is asso-
ciated with the development of T helper (Th)1 immune
responses [25,26]. TLR-9 is expressed at its highest
levels in plasmacytoid dendritic cells (DCs) and B cells
[24], but it has also been found on lung epithelial cells
[27] and fibroblasts [28]. TLR-9 has been shown to be
important in the pathogenesis of gHV68, with TLR-9
-/-
mice being more susceptible to both lytic and latent
gHV68 infection after intraperitoneal inoculation [29].
In this paper, we show that TLR-9 signaling can limit
the exacerbation of the fibrotic response by gHV68
infection in the lung. This exacerbation is not associated
with increased epithelial-cell apoptosis or major altera-
tions in Th1 or Th2 cytokines, but rather, viral infection
in wild-type, but not TLR-9
-/- mice, leads to production
of IFN-b and diminished fibroproliferation. Further-
more, therapeutic administration of CpG oligodeoxynu-
cleotides (ODN) can limit bleomycin-induced
pulmonary fibrosis.
Results
Toll-like receptor-9 signaling protects mice from viral-
induced exacerbation of fibrosis, but has no effect on
fibrotic insults alone
Balb/c and TLR-9
-/- mice were treated with either saline
or bleomycin on day 0. On day 14, a time of established
pulmonary fibrosis [30], the mice were given either
gHV68 infection (5 × 10
4 plaque-forming units (PFU))
or Sham infection (PBS) intranasally. On day 21, a time
point that represents 7 days after infection in the fibro-
tic mice, the lungs were harvested. Collagen content was
determined by Sircol assay (Figure 1A). Baseline col-
lagen levels between Balb/c and TLR-9
-/- mice were
similar, and the mice had similar increases in collagen
levels with bleomycin treatment alone. However, the
TLR-9
-/- mice had a greater increase in collagen on day
21 after viral infection than did wild-type mice (705.4 ±
A
B
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Figure 1 TLR-9
-/- m i c ea r em o r es u s c e p t i b l et ov i r a l
exacerbation of fibrosis. (A) Balb/c and TLR-9
-/- mice were treated
with either saline or bleomycin intratracheally on day 0. They were
then given either sham infection or infection with 5 × 10
4 PFU of
gHV68 on day 14 by intranasal infection. On day 21, lungs were
harvested and Sircol assay was performed. TLR-9
-/- mice were more
susceptible than wild-type mice to viral exacerbation of existing
fibrosis (705.4 ± 52.79 versus 468.6 ± 42 mg collagen/ml; n = 5; P <
0.01). There were no significant differences in collagen levels
between Balb/c and TLR-9
-/- saline-treated mice (255 ± 9.06 versus
227.3 ± 14.95 mg/ml) or between both groups after bleomycin
challenge alone (317.0 ± 43.0 versus 362.5 ± 78.8 mg/ml.) This was
true in three experiments, and the relative increase in collagen
production in bleomycin-treated mice over saline controls was also
not different. (B) Lungs from WT or TLR-9
-/- mice treated with
bleomcyin on day 0 and infected with gHV68 on day 14. Lungs
were harvested for histologic analysis on day 21 and stained with
hematoxylin and eosin. Sections are representative of three mice
examined.
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Page 2 of 1552.8 versus 468.6 ± 42.2 μg/ml; P < 0.01; n = 5). On his-
topathological examination, areas of alveolar fibrosis and
consolidation were found to be increased in TLR-9
-/-
compared with Balb/c mice after fibrotic challenge and
viral infection (Figure 1B). Similar trends were seen with
mice treated with FITC followed by gHV68 or Sham
infection (see Additional file 1, supplemental Figure 1),
although the difference between Balb/c and TLR-9
-/-
mice treated with FITC plus gHV68 did not reach
significance.
Fibrotic mice are more susceptible to viral replication, but
Toll-like receptor-9 deficiency does not alter replication in
the lungs
Guggemoos et al. reported previously that TLR-9
-/- mice
were more susceptible to intraperitoneal gHV68 infec-
tion, but were not more susceptible to intranasal infec-
tion [29]. To determine whether fibrotic challenge
increased viral replication, Balb/c or TLR-9
-/- mice were
infected with 5 × 10
4 PFU gHV68 alone or on day 14
after bleomycin challenge. Lungs were harvested 7 days
after viral infection, and expression levels of the envel-
ope glycoprotein B mRNA (Figure 2A) or the viral DNA
polymerase mRNA (Figure 2B) were measured by real-
time reverse transcription (RT)-PCR. Expression of both
viral transcripts was increased in bleomycin-exposed
lungs compared with naive lungs. However, TLR-9 defi-
ciency did not worsen the viral replication in the lung
compared with Balb/c mice, consistent with previous
findings [29].
In our experience, measurement of lytic viral load by
RT-PCR correlates well with viral titers determined by
plaque assay [14,31].
Alveolar epithelial cells, fibroblasts and fibrocytes all
express Toll-like receptor-9
We have shown previously that alveolar epithelial cells
and mesenchymal cells are target cells for viral infection
within the lung [31,32]. Furthermore, lung epithelial
cells [27] and fibroblasts [28) have been reported to
express TLR-9. Because these cell types are known to be
important in the pathogenesis of fibrosis, we sought to
verify whether TLR-9 was expressed in these cells. The
expression level of TLR-9 was measured by real-time
RT-PCR in isolated AECs, fibroblasts and fibrocytes and
compared with expression levels in DCs, which were
normalized to 1 (Figure 3). Our results confirm that all
three of these cell types express TLR-9, albeit with
mRNA levels that are about 30-fold lower than in DCs.
There was diffuse expression of TLR-9 in lung sections
from Balb/c mice (Figure 3C), with TLR-9 staining in
the bronchial epithelium; att h ea l v e o l a rj u n c t i o n s ,
where there are likely to be type II AECs; and in the
interstitium, where fibroblasts are located. TLR-9
expression was also evaluated in fibroblasts and type II
AECs isolated from Balb/c mice (Figure 3E,G).
Apoptosis of alveolar epithelial cells does not differ
between Balb/c and TLR9
-/- mice treated with bleomycin
and gammaherpesvirus 68
Intranasal infection with gHV68 resulted in viral infec-
tion and replication that was evident in alveolar lining
A
B
g
B
g
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Figure 2 Viral replication is not different in the lungs of Balb/c
and TLR-9
-/- mice. Balb/c or TLR-9
-/- mice were injected with saline
or bleomycin intratracheally on day 0. On day 14, mice received 5 ×
10
4 PFU gamma herpesvirus 68 (gHV68) intranasally. On day 21,
lungs were harvested, and total RNA was prepared and analyzed for
expression of (A) the viral envelope glycoprotein gene (gB) or (B)
viral DNA polymerase. A single mouse in the Balb/c group not
treated with bleomycin was normalized to 1, and all other mice
were plotted relative to this control (n = 5 mice/group,
representative of two experiments). The ΔCT for each group are as
follows: For the gB gene: Balb 4.9 ± 0.5, TLR-9
-/- 5.7 ± 0.5, Balb plus
bleomycin 3.07 ± 0.6, TLR-9
-/- plus bleomycin 2.8 ± 0.7. For the DNA
polymerase gene: Balb 4.5 ± 0.6, TLR-9
-/- 5.4 ± 0.4, Balb plus
bleomycin 3.3 ± 0.6, TLR-9
-/- plus bleomycin 2.8 ± 0.8.
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Figure 3 Alveolar epithelial cells (AECs), fibroblasts and fibrocytes all express Toll-like receptor-9. AECs, fibroblasts, fibrocytes and whole
lungs were isolated from Balb/c, mice and total RNA prepared and analyzed for TLR-9 expression. The data were normalized to the expression
level of TLR-9 in dendritic cells, which was set to 1 (n = 3/group). No TLR-9 message was amplified in cells from TLR-9
-/- mice. (B, C)
Immunohistochemistry was performed on paraffin wax-embedded whole-lung tissue from normal Balb/c mice. (B) Control staining with
secondary antibody only; (C) diffuse TLR-9 staining, with notable staining in the bronchial epithelium, at the alveolar junctions and the
interstitium. Fibroblasts (E) and AECs (G) were isolated from Balb/c mice and fixed. Immunofluorescence staining for TLR-9 shows that both cell
types expressed TLR-9. The control slides with secondary antibody alone (D and F) did not show any auto-fluorescence or non-specific staining.
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epithelial cells (Figure 4A). To determine whether the
viral-induced exacerbation in TLR-9
-/- mice was related
to alterations in AEC apoptosis, we purified AECs from
mice that had been treated with both bleomycin and
gHV68. Assessment of the purity of these AEC preps
showed greater than 95% for e-cadherin (an epithelial-
cell marker) and they contained less than 3% contami-
nation by vimentin-positive cells (fibroblasts and macro-
phages) (see Additional file 1, supplemental Figure 2).
These isolated cells were cultured in Lab-Tek chamber
slides (#177402, Nunc, Rochester, NY) and stained with
an epithelial cell-specific apoptosis antibody that recog-
nizes a caspase cleavage product of cytokeratin 18
Figure 4 Gamma herpesvirus 68 (gHV68) replicates in alveolar epithelial cells (AECs). (A) Wild-type mice were infected with 5 × 10
4 PFU
gHV68 on day 0. On day 7 after infection, frozen sections were prepared, and stained with a rabbit polyclonal antisera against gHV68, or with
non-immune rabbit sera as control. The goat anti-rabbit secondary was linked to alkaline phosphatase. Vivid replication of gHV68 is visible in
alveolar lining cells (original magnification × 100). Sections shown are representative of four mice examined. (B) AECs were isolated from lungs
of Balb/c or TLR-9
-/- mice treated with bleomycin plus gHV68 on day 21, and were cultured on fibronectin-coated slides (TiterTek). Sections were
stained with antibodies (M30 Cytodeath), and the number of positive cells per high power field (HPF; ×400) were calculated (n = 30 HPF per
genotype). (C) AECs were isolated from Balb/c or TLR-9
-/- mice and cells were infected in vitro with 0.01 or 0.001 PFU gHV68 for 48 hours. Cell
lysates were then analyzed for cleaved caspase 3 by western blotting. Data are from one experiment, representative of two.
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field (HPF) was determined. There was an equivalent
level of apoptosis in epithelial cells isolated from each
strain (Figure 4B).
AECs were also isolated from naïve Balb/c or TLR-9
-/-
mice, and these cells were infected with either 0.01 or
0.001 MOI (multiplicity of infection) of gHV68 for 48
hours, before cell lysates were prepared and analyzed for
cleaved caspase 3 by western blotting. Viral infection
induced caspase 3 activation in both genotypes, but
there was no evidence of increased caspase 3 activation
in the TLR-9
-/- cells compared with the Balb/c cells
(Figure 4C). Thus, the reason TLR-9
-/- mice develop
worse fibrosis does not appear to be related to altera-
tions in AEC apoptosis.
Balb/c and TLR9
-/- alveolar epithelial cells are equivalent
in their ability to suppress fibroproliferation
To determine whether there was an inherent difference
in the ability of AECs from Balb/c and TLR-9
-/- mice to
limit fibroproliferation, AECsw e r ei s o l a t e df r o me i t h e r
Balb/c or TLR-9
-/- mice, and these cells were co-cul-
tured with fibroblasts from either Balb/c mice (see
Additional file 1, supplementary Figure 3A) or with
fibroblasts from TLR-9
-/- mice (see Additional file 1,
supplementary Figure 3B). AECs from both strains were
equivalent in their ability to limit fibroproliferation over
a 24 h period.
TLR9
-/- mice treated with bleomycin plus
gammaherpesvirus 68 show increased CD8 recruitment
To determine the magnitude and composition of the
inflammatory response that occurs after bleomycin with
or without gHV68 infection, mice of both genotypes were
treated with bleomycin on day 0. On day 14, mice were
either infected with gHV68 or were sham-infected. On day
21, lungs were collected, and digested with collagenase
and DNAse to isolate lung leukocytes. Viral infection sti-
mulates an inflammatory response that was greater than
that noted in mice treated with bleomycin alone (Figure
5A). However, there was no difference in the magnitude of
the inflammatory-cell influx between Balb/c and TLR-9
-/-
strains. When particular cell types were analyzed by flow
cytometry, it was found that after infection, TLR-9
-/- mice
had a higher percentage of CD8+ T cells in the lung, and
both strains of mice had a reduction in B cells (Figure 5B).
Both strains tended to have higher numbers of neutrophils
after infection, as expected.
Figure 5 Inflammatory responses are similar in Balb/c and TLR-9
-/- mice. Mice were treated with bleomycin on day 0, and were given 5 ×
10
4 PFU gHV68 intranasally on day 14. On day 21, lungs were collected and subjected to digestion with collagenase and DNAse. (A) Lung
leukocytes were enumerated (n = 4 mice/group, representative of four experiments). (B) Isolated lung leukocytes were examined by flow
cytometry for the percentage surface expression of CD4, CD8, CD19, Gr-1 (PMNs) and DX5 (NK cells). Samples were gated on CD45+ cells first.
Percentages of lymphocytes were then determined within a lymphocyte gate. Gr-1 percentages were gated on CD45+ non-lymphocyte sized
cells (n = 4/group representative of two experiments). **P < 0.01 for CD8 in TLR-9
-/- mice treated with bleomycin plus gHV68 compared with
Balb/c with same treatment. For B cells, virally infected mice were significantly different from mice treated with bleomycin alone in both
genotypes (P < 0.01).
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of fibrosis in wild-type mice correlated with viral-induced
fibrocyte accumulation in th el u n g[ 1 4 ] .T od e t e r m i n e
whether fibrocyte recruitment was different between
Balb/c and TLR-9
-/- mice treated with bleomycin plus
gHV68, lung leukocytes were isolated by collagenase and
DNAse digestion on day 21, and these cells were stained
for CD45+ collagen 1+ cells. Lungs of Balb/c mice con-
tained 1.2 ± 0.14% fibrocytes, which was not significantly
different from the 2.02 ± 0.5% seen in TLR-9
-/- mice (n =
4, P = NS). Thus, differential recruitment of fibrocytes
was not seen in TLR-9
-/- versus control mice.
TLR9
-/- mice have reduced T helper 2 responses during
viral exacerbation of fibrosis
Balb/c mice and TLR-9
-/- mice were treated with bleomy-
cin on day 0. On day 14 the mice were given gHV68
infection (5 × 10
4 PFU). On days 0, 14, 17 and 21, lungs
were harvested, and whole-lung homogenates were
assayed for Th1 and Th2 cytokines by ELISA. Because
gHV68 has been shown to be fibrotic in Th2-biased mice
[11], we wanted to determine whether TLR-9
-/- mice had
increased Th2 profiles. There were modest fluctuations
in the Th2 cytokines over the 21 day course, but no evi-
d e n c eo faT h 2s k e w i n gi nt h eT L R - 9
-/- mice (see Addi-
tional file 1, supplementary F i g u r e4 A ,B ) .I nf a c t ,w h e n
treated with bleomycin plus gHV68, the TLR-9
-/- mice
had decreased levels of interleuking (IL)-4 and IL-13 on
day 21 compared with baseline measurements; these
trends were not noted in the Balb/c mice. When Th1
cytokines were analyzed, both Balb/c and TLR-9
-/- mice
mounted strong interferon-g responses by day 21 of the
experiment, which corresponded to day 7 after viral
infection (see Additional file 1, supplementary Figure 4
(C). By contrast, IL-12 levels diminished after infection in
both genotypes (see Additional file 1, supplementary Fig-
ure 4(D). There were few changes in expression profiles
of IL-17 or tumor necrosis factor-a (see Additional file 1
supplementary Figure 4E and 4F). Additionally, when
total TGF-b levels were measured after acid activation by
ELISA on day 21 following bleomycin plus gHV68 infec-
tion, there was no significant difference between the gen-
otypes (see Additional file 1, supplementary Figure 5).
TLR9
-/- mice are defective in IFN-b expression post
challenge
TLR-9 stimulation is known to be crucial for type I IFN
production [33]. Thus, we sought to determine whether
the TLR-9
-/- mice had differences in production of IFN-
b after bleomycin plus gHV68 challenge. Mice were
given bleomycin on day 0 and were infected with
gHV68 on day 14. Lungs were harvested on days 0, 14,
17 and 21, and IFN-b expression was determined in
whole-lung homogenates by ELISA. Bleomycin challenge
resulted in a loss of IFN-b expression in both genotypes
(Figure 6A), suggesting that this reduction is TLR-9-
independent. Following viral infection on day 14, pro-
duction of IFN-b was restored by day 21 (a week after
viral challenge) in Balb/c mice, but there was a signifi-
cant reduction in IFN-b production in TLR-9
-/- mice.
Furthermore, when fibroblasts isolated from Balb/c or
TLR-9
-/- mice were infected with 0.01 PFU gHV68 in
vitro for 24 hours, and mRNA was analyzed for expres-
sion of IFN-b, expression in TLR-9
-/- fibroblasts was
reduced nearly 10-fold (Figure 6B).
Gammaherpesvirus 68 infection induces IFN-b production,
which limits fibroblast proliferation
To determine whether infected fibroblasts could produce
IFN-b, Balb/c fibroblasts were cultured at 50,000 cells/
well an infected with 0, 0.1, 0.01 and 0.001 MOI gHV68
for 24 h. Culture supernatants were harvested and ana-
lyzed for IFN-b production by ELISA (Figure 7A). These
data show that even at low MOI, gHV68 could stimulate
IFN-b production. To determine whether these
**
B
A
p=0.007
Figure 6 TLR-9
-/- mice are defective in interferon (IFN)-b
production. (A) Balb/c or TLR-9
-/- mice were injected with
bleomycin on day 0. On day 14 mice received gHV68 intranasally.
Lungs were harvested on days 0, 14, 17 and 21, and lung
homogenates were prepared and analyzed by ELISA for IFN-b (n =
5 mice/group). (B) Fibroblasts isolated from Balb/c or TLR-9
-/- mice
were infected in vitro with 0.01 PFU gHV68 and total RNA was
prepared after 24 h of infection for analysis of IFN-b by real-time RT-
PCR. The mean of the Balb/c samples was set to 1, n = 5/group.
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Balb/c and TLR-9
-/- fibroblasts were cultured at 5000
cells/well in the presence of increasing concentrations of
recombinant IFN-b. Doses as low as 7.5 pg/ml were
effective in limiting fibroblast proliferation in both strains
(Figure 7B).
Gammaherpesvirus 68 infection reduces proliferation of
Balb/c, but not TLR9
-/- fibroblasts
Based on the IFN-b results (Figure 7) and the previous
observations that type I interferons inhibit lung fibroblast
proliferation [34], we hypothesized that viral infection of
Balb/c fibroblasts would result in reduced fibroblast prolif-
eration soon after infection. Indeed, infection of Balb/c
fibroblasts with 0.01 PFU/cell gHV68 resulted in dimin-
ished proliferation when measured at 24 hours after infec-
tion (Figure 8A). By contrast, viral infection of TLR-9
-/-
fibroblasts had no effect on proliferation within this time
frame (Figure 8B). These results suggest that induction of
IFN-b by viral infection in the Balb/c mice may serve to
limit the degree of exacerbation caused by viral infection.
CpG therapy can limit bleomycin-induced fibrosis
Our results suggested that TLR-9 stimulation during
viral exacerbation of fibrosis might be protective. Thus,
we investigated whether forced (non-infectious) stimula-
tion of TLR-9 in bleomycin-induced fibrosis might also
be protective. To test this, we first administered CpG
ODN to the lungs of Balb/c and TLR-9
-/- mice, starting
on day 14 after challenge, and harvested the lungs for
collagen deposition on day 21. Unfortunately, in these
experiments, the fibrotic response to bleomycin (from
Sigma) was weaker than expected in the Balb/c back-
ground, making it difficult to ascertain whether CpG
ODN treatment was effective. Thus, we repeated these
experiments using the C57Bl/6 strain, which is has a
more robust fibrotic response to bleomycin and also
used a clinical source of the drug(Blenoxane; Bristol-
Myers Squibb, New York, NY, USA) [35]. Administra-
tion of a single dose of 50 μg CpG ODN intranasally on
day 14 after bleomycin (Figure 9A) attenuated the fibro-
tic response measured on day 28 by hydroxyproline
assay (Figure 9B). Representative histology sections
stained with Masson’s trichrome also showed substantial
improvement in the fibrotic outcome (Figure 9C).
Discussion
We have previously shown that a gammaherpesvirus
infection can exacerbate established FITC-induced fibro-
sis in a murine model [14]. In this study, we found that
TLR-9 signaling plays a role in limiting the profibrotic
exacerbations of gammaherpesviral infection. There are
many potential mechanisms by which TLR-9 signaling
might influence the fibrotic environment during viral
infection. One possible mechanism is simply by limiting
viral replication. Guggemoos et al.s h o w e dt h a tT L R - 9
signaling is important in control of gHV68 infection
when given intraperitoneal l y[ 2 9 ] ;h o w e v e r ,t h e yw e r e
not able to show that TLR-9 signaling in the lung was
important in controlling an intranasal infection with
gHV68. Our data are consistent with this finding.
Although replication of the virus was greater in mice
treated with bleomycin compared with non-fibrotic
mice, the absence of TLR-9 had little effect on viral
gene expression in either group. Although it is not
entirely clear why viral replication is enhanced in fibro-
tic mice, it is likely that proinflammatory and profibrotic
factors enhance viral gene transcription. In support of
this hypothesis, prostaglandin E2 has been shown to
promote viral replication [36]. Thus, our results confirm
that TLR-9 signaling is not required for control of lytic
gHV68 infection in the lung. The reasons why TLR-9
would differentially regulate lung versus peritoneal
infection probably reflect the differences in the cell
populations that are initially infected in each site.
Within the lung, AECs are one of the primary cell
types infected with gHV68, as confirmed by our immu-
nohistochemical findings in this study (Figure 4A) and
our previous studies [31,32]. Although it is known that
A
B
Figure 7 Gamma herpesvirus 68 (gHV68) infection induces
interferon (IFN)-b, which in turn limits fibroblast proliferation.
(A) Fibroblasts from Balb/c mice were infected with 0, 0.001, 0.01
and 0.1 MOI gHV68 in vitro, and levels of IFN-b in the supernatant
were measured 24 hours later (n = 6/group). (B) Fibroblasts from
(left) Balb/c or (right) TLR-9
-/- mice were cultured at 5000 cells/well
in the presence of increasing concentrations of IFN-b. IFN-b limited
proliferation of fibroblasts at all doses tested (n = 6/group).
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Figure 8 Infection by gamma herpesvirus 68 (gHV68) limits Balb/c, but not TLR-9
-/- fibroblast proliferation. Fibroblasts from (A) Balb/c
and (B) TLR-9
-/- mice were infected in vitro with 0.01 PFU gHV68, and proliferation was measured 24 hours later by
3H-thymidine incorporation
(n = 6 samples/group). The results are presented as the percentage proliferation compared with the highest value in the uninfected fibroblasts.
In the wild-type mice, infection resulted in a 35.2% reduction in proliferation (67.5% ± 8.9% versus 32.3% ± 2.7%, P = 0.003), whereas in the TLR-
9
-/- mice, infection did not result in a significant change in proliferation (83.2% ± 5.0% versus 79.8% ± 3.9%, P = 0.56).
A
B
C
Figure 9 CpG oligodeoxynucleotides (ODN) stimulation lessens bleomycin-induced fibrosis. (A) C57Bl/6 male mice were injected with
0.25U bleomycin intrathecally on day 0. (B) On day 14, 50 μg CpG ODN was administered intranasally, and lung collagen was measured by
hyroxyproline on day 28. (C) Lung sections were stained with Masson’s trichrome to detect blue coloration indicative of collagen (n = 5 mice/
group).
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and enable establishment of latent infection [37-39],
previous studies in human cells and tissues have sug-
gested a role for gammaherpesviruses in the induction
of AEC apoptosis [10,23]. Furthermore, TLR-9 stimula-
tion has been shown to inhibit macrophage apoptosis
[40]. Thus, we were surprised to discover that levels of
apoptosis in AECs isolated from mice treated with bleo-
mycin plusgHV68 were similar between Balb/c and
TLR-9
-/- genotypes. This was true regardless of whether
apoptosis was assessed by M30 staining or caspase
activation.
One important aspect of AEC function is to limit
fibroproliferation. Profibrotic stimuli (for example, che-
mokine (C-C motif) ligand 2 (CCL2)) are known to alter
the ability of isolated AECs to limit fibroproliferation
[41]. Thus, we sought to determine whether there were
basal differences in the ability of the AECs from Balb/c
or TLR-9
-/- mice to control fibroblast proliferation.
However, AECs from both genotypes of mice were
equivalent in their ability to limit fibroblast proliferation
from both strains. Taken together, we could not find
substantial evidence of altered AEC apoptosis or func-
tion to explain the exaggerated viral-induced fibrotic
response noted in TLR-9
-/- mice.
We next investigated the inflammatory response
between Balb/c and TLR-9
-/- mice treated with bleomy-
cin plus gHV68. After viral exacerbation, both genotypes
of mice had an increase in total numbers of inflamma-
tory cells, but there were few differences noted in the
particular cell types recruited. There were no significant
differences in fibrocyte accumulation, or in the percen-
tages of neutrophils or CD4, natural killer or B cells
between genotypes. The TLR-9
-/- mice did have a higher
percentage of CD8+ cells, and it is possible that if acti-
vated, these CD8+ cells could contribute to tissue
damage, which might exaggerate the fibrotic response in
the TLR-9
-/- mice. Both genotypes had a loss of B cells
after infection, and we believe this represents the migra-
tion of B cells to the spleen, the known major reservoir
for latent viral infection [42].
Because TLR-9 signaling leads to NFB activation and
the production of Th1 cytokines [43], it seemed likely
that TLR-9
-/- mice would have a more Th2-biased cyto-
kine environment. Because Th2-biased mice are known
to be prone to the development of fibrosis in response
to infection with gHV68 [11], it was possible that a cyto-
kine imbalance could explain the exacerbation of fibrosis
in TLR-9
-/- mice. However, there was no evidence of
Th2 skewing or defective Th1 signaling in the TLR-9
-/-
mice during the acute response to bleomycin and infec-
tion. In fact, IL-4 and IL-13 levels were reduced on day
21 after bleomycin plus gHV68 administration in TLR-
9
-/- m i c e .W ew e r es u r p r i s e dt h a tI F N - g was not
diminished in the TLR-9
-/- mice, and we believe that
this may reflect the fact that in AECs at least, activation
of other TLRs may help to stimulate NFB activation
for IFN-g production. We confirmed that lung AECs
from TLR-9
-/- mice express normal levels of TLR7 and
TLR8, for instance (data not shown). Additionally, dif-
ferences in production of TGF-b were not noted
between genotypes. The observation that fibrosis is
exaggerated despite strong induction of IFN-g confirms
our previous findings of viral exacerbation in the C57Bl/
6 background [14]. Thus, we conclude that neither
reduced production of Th1 cytokines nor increased pro-
duction of Th2 cytokines in response to infection can
explain the enhanced exacerbation of fibrosis noted in
TLR-9
-/- mice.
Not surprisingly, the one cytokine whose production
was different between Balb/c and TLR-9
-/- mice was
IFN-b. TLR-9 stimulation is known to induce type I
interferons [33]. Levels of IFN-b were reduced after
bleomycin plus virus in whole-lung homogenates and in
infected fibroblasts. It is interesting that after bleomycin
administration alone, levels of IFN-b were reduced (Fig-
ure 6A). The fact that this happened in both Balb/c and
TLR-9
-/- mice suggest a TLR-9-indepdent mechanism
f o rt h er e d u c t i o ni nI F N - b after a fibrotic insult. This
should not necessarily be interpreted to mean that bleo-
mycin causes a reduction inT L R - 9e x p r e s s i o n ,a sw e
have no evidence of that, at least in fibroblasts isolated
from fibrotic mice (data not shown). As IFN-b is known
to be a potent inhibitor of lung fibroblast proliferation
[34], a fact we have confirmed (Figure 7), it is reason-
able to conclude that early viral infection of fibroblasts
would result in the stimulation of TLR-9 by viral CpG
DNA sequences and a concomitant decrease in fibro-
blast proliferation. In fact, we found that fibroblasts
from Balb/c mice potently upregulated IFN-b secretion
in response to even low-level infection. Furthermore,
exogenous IFN-b could limit proliferation of fibroblast
from both strains, suggesting that the defect in TLR-9
-/-
mice is not sensitivity to, but rather production of, IFN-
b. Taken together, we conclude that although viral
infection after fibrotic challenge increases the fibrotic
response of both strains, the more extensive exacerba-
tion of fibrosis noted in the TLR-9
-/- mice is most likely
due to deficiencies in IFN-b production, which in turn
allow for increased fibroproliferation. When cell number
and viral dose were equivalent, fibroproliferation was
inhibited in Balb/c, but not TLR-9
-/- mice (Figure 8).
Because there may be some TLR-9-independent signal-
ing that leads to IFN-b production in the lung by day 7
after infection (Figure 6A), it is possible that at later
time points, sufficient IFN-b may be available to limit
fibroproliferation even in TLR-9
-/- mice. It is important
to remember that secretion of IFN-b in the lung would
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blasts, not just those that happened to be infected.
TLR-9
-/- mice did not respond differently from wild-
type mice to bleomycin alone or FITC alone. These
results suggest that fibrotic insults alone may not gener-
ate endogenous ligands for TLR-9 stimulation. Thus, we
next wanted to determine whether therapeutic stimula-
tion of TLR-9 with CpG ODN could protect against
fibrotic challenge. We initially tried to perform these
experiments in the Balb/c background, but had poor
responses to bleomycin in two separate experiments.
Although levels of collagen were somewhat lower in
CpG ODN-treated mice than in control mice, the over-
all levels of fibrosis were so low that meaningful inter-
pretations of the data were not possible. Given the
expense of these experiments, we chose to perform
them in the C57Bl/6 background, which has a more
reproducible fibrotic response to bleomycin or Blenox-
ane [35]. We found that mice treated intranasally with
CpG ODN were significantly protected from the devel-
opment of bleomycin-induced fibrosis (Figure 9).
Although these results in murine studies were very
exciting, recent studies in human cells have made it
clear that it is unlikely that these results can be extrapo-
lated to humans.
Our results are not the first to describe an enhanced
fibrotic response in TLR-9
-/- mice. Earlier studies have
shown that granulomas that form in response to Schis-
tosoma mansoni eggs in TLR9-/- mice are larger and
have more collagen deposition within the granuloma
than in wild-type mice [44]. However, in that study, the
results were associated with diminished Th1 and aug-
mented Th2 responses, probably reflecting the strong
Th2-skewing nature of the S. mansoni egg antigens,
whereas we used a Th1-inducing viral infection. Thus,
there are now at least two examples of TLR-9 signaling
showing a protective effect in lung-fibrosis models in
mice. By contrast, Meneghin et al.f o u n dt h a tT L R - 9
expression in human lung fibroblasts promotes myofi-
broblast differentiation [28], and was anticipated to wor-
sen fibrotic disease. This human study also found that
TLR-9 was expressed at low levels in surgical lung biop-
sies of normal subjects, but was dramatically upregu-
lated in the biopsies from patients with fibrotic lung
diseases. These data suggest that TLR-9 expression
might be low in normal human lung fibroblasts,
whereas our studies suggest that murine lung fibroblasts
express this receptor constitutively. In addition, TLR-9
expression in human lung epithelium is modest com-
pared with that at other sites in the body [45]. Studies
in both human lung fibroblasts and human hepatic stel-
late cells have shown the ability of TLR-9 stimulation
via CpG ODN to induce myofibroblast differentiation
[28,46]. Furthermore, expression of TLR-9 on fibroblasts
obtained from initial surgical lung biopsies of patients
with IPF can distinguish patients with rapid disease pro-
gression (TLR-9-positive) from patients with a slower
disease course (TLR-9-negative) [47]. Thus, it seems
that in humans, TLR-9 stimulation may promote fibro-
tic reactions, whereas in mice, it may protect. Another
important difference that may explain the improved
outcomes in TLR-9-expressing mice is that mice have a
larger repertoire of CpG-responsive hematopoietic cells.
In mice, all DC subsets, B cells and macrophages
respond to CpG ODN, whereas in humans, only plas-
macytoid DCs and B cells respond [48]. Thus, it is likely
that production of IFN-b in response to TLR-9 stimula-
tion is greater in the murine system than it would be in
humans. Collectively, these studies identify important
differences between mice and men, and thus suggest
that CpG therapy, although beneficial in rodent models
of fibrosis, is unlikely to be beneficial for human treat-
ment of IPF.
Conclusions
TLR-9 signaling is protective during viral exacerbation
of murine pulmonary fibrosis. This is probably due to
increased levels of IFN-b, which limit fibroblast prolif-
eration. There is no evidence that TLR-9 signaling dur-
ing a viral exacerbation of pulmonary fibrosis alters
alveolar epithelial-cell apoptosis. As TLR-9 signaling in
human IPF fibroblasts appears to lead to a more profi-
brotic phenotype, these data highlight important differ-
ences between the human and mouse disease, and the
limitations of our current animal models of pulmonary
fibrosis.
Methods
The Animal Use Committee at the University of Michi-
gan (Ann Arbor, MI, USA) approved all protocols and
experiments described.
Mice
BALB/c and C57Bl/6 mice (Jackson Laboratories, Bar
H a r b o r ,M E ,U S A ) ,a g e d6t o8w e e k so l da n dm a t c h e d
for age and sex, were used. TLR-9
-/- mice backcrossed
to Balb/c (University of Michigan, East Lansing, MI,
USA) have been described previously [25].
Fluoroscein isothiocyanate and bleomycin models of
pulmonary fibrosis
Intratracheal (IT) inoculation of FITC (50 μlo fa2 . 8
mg/ml solution in saline) or bleomycin sulfate (0.035
per mouse in a 50 μl volume) (both from Sigma Chemi-
cal Co., St. Louis, MO, USA) was performed as
described previously [49]. In C57Bl/6 mice, clinical
grade bleomycin sulfate (Blenoxane; Bristol-Myers
Squibb, New York, NY, USA) was utilized.
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Mice were anesthetized with ketamine and xylazine. Into
20 μls a l i n ew e r es u s p e n d e d5× 1 0
4 PFU of gHV68
(American Type Culture Collection, Manassas, VA,
USA), which were then delivered intranasally to each
mouse. Sham infections consisted of intranasal delivery
of 20 μl of saline.
Lung collagen measurements
Total lung collagen measurements were made as
described previously [16], using the Sircol collagen dye-
binding assay (Accurate, Westbury, NY, USA). In some
experiments, collagen content was estimated by hydro-
xyproline assay, as described previously [50].
Histology
Lungs were inflated with 10% neutral-buffered formalin,
and embedded in paraffin wax. Thin sections (5 μm) of
lung were then stained with either hematoxylin and
eosin or Masson’s trichrome. For viral immunohisto-
chemistry, frozen sections were prepared from infected
mice, and gHV68 infection was detected using a rabbit
polyclonal anti-gHV68 sera [51] (kindly provided by Dr
Skip Virgin, Washington University School of Medicine,
St. Louis, MO, USA) and detected with a goat anti-rab-
b i ts e c o n d a r ya n t i b o d yc o n j u g a t e dt oa l k a l i n ep h o s p h a -
tase (Vectastain-ABC-AP kit for rabbit IgG (AK5001),
Vector Laboratories, Burlingame, CA, USA).
TLR-9 immunohistochemistry was performed on wax-
embedded tissues. The tissues were dewaxed and then
blocked with H2O2 for antigen retrieval. They were
incubated overnight at 4°C with a 1:50 of the primary
antibody, a rabbit polyclonal antibody to TLR-9 (IMG-
431; Imgenex Corp., San Diego, CA, USA). They were
then incubated with biotin-labelled anti-rabbit IgG 1:500
(V1011; Vector Laboratories Inc., Burlingame, CA, USA)
for 30 minutes at room temperature, followed by diami-
nobenzidine (catalog number 54-10-00; KPL Inc.,
Gaithersburg, MD, USA) for 10 minutes at room tem-
perature. Control slides were stained with secondary
antibody only.
TLR-9 immunofluorescence staining was performed
on isolated cells using a mouse monoclonal primary
antibody at 1:50 dilution (IMG-305A; Imgenex Corp)
and Alexa Flour 555 goat anti-mouse IgG (catalog num-
ber A21424; Invitrogen Corp., Carlsbad, CA, USA). The
slides were then mounted using anti-fade reagent (Pro-
long Gold; Invitrogen) with 4’,6-diamidino-2-phenylin-
dole (catalog number P36931, Invitrogen). Control slides
were stained with secondary antibody only.
ELISA
Cytokine levels were measured in whole-lung homoge-
nates using commercial kits (R&D Systems;
Minneapolis, MN, USA) according to the manufacturer’s
instructions. IFN-b was also measured using a commer-
cial kit (PBL Biomedical Laboratories, Piscataway, NJ,
USA).
Flow cytometry
For fibrocyte enumeration, cells obtained by collagenase
digestion were incubated for 15 minutes on ice with Fc
block (clone 24G2; BD PharMingen, San Diego, CA,
USA) before surface staining with CD45-PerCPCy5.5
(BD PharMingen) followed by fixation and permeabiliza-
tion using a kit (Cytofix/cytoperm Kit; BD PharMingen)
according to the manufacturer’s instructions. Cells were
then blocked with goat IgG before staining with collagen
1 (rabbit anti-mouse) (Rockland, Gilbertsville, PA, USA)
followed by a goat anti-rabbit phycoerythrin-conjugated
secondary antibody (Jackson Immunoresearch, West
Grove, PA, USA). Rabbit IgG (Jackson Immunoresearch)
was used as an isotype control in place of the anti-col-
lagen antibody. Cells were analyzed on a flow cytometer
(FACSCalibur; BD Biosciences, Mountain View, CA,
USA).
For other leukocyte subsets, cells were stained with Fc
block followed by surface staining for CD45, CD4, CD8,
CD19, Gr-1 or DX-5 using directly conjugated antibo-
dies (BD PharMingen).
Isolation of alveolar epithelial cells
Type II alveolar epithelial cells were isolated and puri-
fied using a protocol published previously [52].
Isolation of fibroblasts and fibrocytes
Mice were perfused with saline, and lung lobes were
removed and minced with scissors. The minced tissue
was cultured for 14 days in complete media to obtain a
population of plastic-adherent mesenchymal cells. Fibro-
blasts were then negatively selected using anti-CD45-
conjugated magnetic beads. Fibrocytes were the posi-
tively selected CD45 fraction.
Isolation of dendritic cells
Bone marrow was cultured in complete media contain-
ing granulocyte-macrophage colony-stimulating factor
(10 ng/ml) for 5 days. These cells were used as a posi-
tive control for TLR-9 expression by real-time RT-PCR.
real-time reverse transcriptase PCR
Real-time RT-PCR was performed on a thermocycler
(ABI Prism 7000; Applied Biosystems, Foster City,
CA) using a protocol described previously [53). Genes
of interest included the gHV68 lytic outer envelope
glycoprotein B (gB), viral DNA polymerase, TLR-9
and IFN-b. Primer sequences and probes are listed in
Table 1.
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AECs were fixed and stained, according to manufac-
turer’s instructions, with an antibody (M30 Cytodeath;
Roche, Indianapolis, IN, USA) that detects a caspase
cleavage product of cytokeratin 18 in epithelial cells.
Caspase 3 western blotting
Western blots were performed as described previously
using the follwoing antibodies: for cleaved caspase 3, a
rabbit anti-human/mouse antibody (MAB835; R&D Sys-
tems) and for b-actin, a mouse monoclonal antibody
(Sigma, cat# AC-74), with secondary antibodies for
cleaved caspase 3 goat anti-rabbit (catalog number
31462; Pierce Protein Research Products, Thermo
Fischer Scientific, Rockford, IL) and b-actin goat anti-
mouse (catalog number 31432; Pierce Protein Research
Products, Thermo Fischer Scientific, Rockford, IL).
Proliferation assays
Fibroblasts were seeded at 5000 cells/well in 96-well
flat-bottomed plates.
3H-thymidine (1 μCi) was added to
each well during the final 16 hours. Cells were harvested
onto glass-fiber filters, and the incorporated radioactivity
was determined by scintillation counting. In some
experiments, IFN-b (Cellsciences, Canton, MA, USA)
was added during culture.
In vivo CpG delivery
Specific-pathogen-free male C57BL/6 (wild-type (WT))
mice (Taconic, Germantown, NY, USA) 6 to 8 weeks of
age were used. WT mice received 0.05 U of bleomycin sul-
fate (Blenoxane; Bristol-Meyers Pharmaceuticals, Evans-
ville, IN, USA) dissolved in PBS (approximately 1.7 U/kg)
via IT injection. Fourteen days later, all groups of mice
were mildly anesthetized, and received a single bolus (50
μg) of CpG ODN (dissolved in sterile saline) by intranasal
delivery. Groups of WT mice (n = 5 to 10 per timepoint)
were monitored for survival. Mice were killed by cervical
dislocation 28 days after the IT challenge with bleomycin,
and whole-lung tissue was dissected for histological and
biochemical analysis of hydroxyproline content. Untreated
mice (n = 5) did not receive bleomycin, and this time
point was designated as day 0.
Statistical analyses
All calculations were performed using Prism 5.0 soft-
ware (GraphPad Software, San Diego, CA, USA). Values
are expressed as means ± SEM. Two-sample t-tests
were used for comparisons of the means when two
groups were compared. One-way ANOVA was used for
comparisons of three or more groups with Bonferroni
or Dunnet post-hoc test analyses depending on whether
all groups were compared with each other or all groups
were compared with a single control group. P ≤ 0.05
was considered significant.
Additional material
Additional file 1: Supplementary data and figures are included in a
pdf file titled ‘supplementary Figures’. Supplemental Figure 1: TLR9
protects from gammaherpesvirus-induced exacerbation of FITC-induced
fibrosis. A) Balb/c or TLR9-/- mice were injected with saline or 50 μlo fa
2.8 mg/ml solution of FITC on day 0. On day 14, FITC-treated mice were
mock-infected or infected with gHV-68. On day 21 lungs were harvested
for collagen content determination by hydroxyproline assay (n = 3 per
group in saline and n = 8 in other groups). B) H&E staining of lungs from
FITC + gHV-68 groups on day 21. Representative of n = 3 other mice.
Supplemental Figure 2: Immunohistochemistry demonstrating purity of
AEC culture. AECs were isolated from mice treated with bleomycin +
gHV-68 and were cultured on fibronectin-coated titer tek slides. Cells
were then fixed and stained with e-cadherin or vimentin to demonstrate
purity. Alkaline phosphatase detection shows that cells are >95% e-
cadherin+ and less than 3% vimentin positive. Supplemental Figure 3:
Balb/c and TLR9
-/- alveolar epithelial cells are equivalent in their ability to
suppress fibroproliferation. AECs were isolated from Balb/or TLR9-/- naïve
mice and were plated at 50,000 cells per well on fibronectin-coated 96
well plates. Fibroblasts at 5000 cells per well from Balb/c mice (panel A)
or TLR9-/- mice (panel B) were added to each well and proliferation of
fibroblasts was measured by
3H-thymidine incorporation after 24 h. AECs
cultured alone had proliferation rates of less than 800 cpm., n = 12 per
group. Supplemental Figure 4: TLR9
-/- mice have reduced T helper 2
responses during viral exacerbation of fibrosis. Lungs were harvested
from Balb/c and TLR9-/- mice after bleomycin and gHV68 infection on
days 0, 14, 17 and 21. Whole lung homogenates were made and the
levels of IL-4, IL-13, INFg, IL-12, IL-17 and TNFa were measured by ELISA.
Supplemental Figure 5: No differences in TGFb activation were seen
between WT and TLR9-/- mice during a viral exacerbation of pulmonary
fibrosis. Lungs were harvested from Balb/c and TLR9-/- mice treated in
vivo with bleomcyin and gHV68 on day 21. Lung homogenates were
acid-treated to activate total TGFb and were then analyzed by ELISA, n =
5.
List of abbreviations
ELISA: enzyme-linked immunosorbent assay; PBS: phosphate-buffered saline.
Table 1 Primer and Probe sequences for real-time RT-PCR
Gene Oligo Sequence 5’®3’
Glycoprotein B
a Forward CGCTCATTACGGCCCAAA
Reverse ACCACGCCCTGGACAACTC
Probe TTGCCTATGACAAGCTGACCACCA
b-actin Forward CCGTGAAAAGATGACCCAGATC
Reverse CACAGCCTGGATGGCTACGT
Probe TTTGAGACCTTCAACACCCCCAGCCA
Interferon-b Forward TGACGGAGAAGATGCAGAAGAG
Reverse TGGAGTTCATCCAGGAGACGTA
Probe TGCCTTTGCCATCCAAGAGATGCTC
Toll-like receptor-9 Forward GAGTACTTGATGTGGGTGGGAATT
Reverse GCCACATTCTATACAGGGATTGG
Probe CCGTCGCTGCGACCATGCC
DNA polymerase Forward ACAGCAGCTGGCCATAAAGG
Reverse TCCTGCCCTGGAAAGTGATG
Probe CCTCTGGAATGTTGCCTTGCCTCCA
aGamma herpesvirus 68 open-reading frame 8.
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